Metabolic Disorders
Significant reduction in 6-year fragility fracture risk with zoledronate vs placebo for osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082

Osteoarthritis
Zoledronic acid has no continued benefit beyond 6 years for osteoporosis
J Bone Miner Res. 2015 May;30(5):934-44.

Metabolic Disorders
Antiresorptive effects of single zoledronate dose are sustained for 3 years
J Bone Miner Res. 2010 Oct;25(10):2251-5

Metabolic Disorders
Five-year follow-up of the effects of calcium supplementation in postmenopausal women
Osteoporos Int. 2014 Jan;25(1):297-304. doi: 10.1007/s00198-013-2526-z. Epub 2013 Oct 10.

General Orthopaedics
Effects of 2.5mg zoledronate are long-lasting and similar to 5mg dose in osteopenic women
J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009.

Spine
Annual infusion of zoledronic acid reduces days of back pain, disability, and bed rest
J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292

General Orthopaedics
The effect of 3 versus 6 years of zoledronic acid treatment on femoral neck-BMD
J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494

General Orthopaedics
Substantial anti-resorptive effects achieved with 1mg and 2.5mg doses of zoledronate
J Clin Endocrinol Metab. 2012 Jan;97(1):286-92. doi: 10.1210/jc.2011-2081. Epub 2011 Nov 9

General Orthopaedics
Denosumab reduces risk of fractures in post-menopausal women
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.